Genetic inflammatory factors predict restenosis after percutaneous coronary interventions

被引:68
作者
Monraats, PS
Pires, NMM
Agema, WRP
Zwinderman, AH
Schepers, A
de Maat, MPM
Doevendans, PA
de Winter, RJ
Tio, RA
Waltenberger, J
Frants, RR
Quax, PHA
van Vlijmen, BJM
Atsma, DE
van der Laarse, A
van der Wall, EE
Jukema, JW
机构
[1] Leiden Univ, Med Ctr, Dept Cardiol, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Dept Human Genet, Ctr Human & Clin Genet, NL-2300 RC Leiden, Netherlands
[4] Interuniv Cardiol Inst Netherlands, Utrecht, Netherlands
[5] TNO, PG, Gaubius Lab, Leiden, Netherlands
[6] Acad Med Ctr, Dept Med Stat, Amsterdam, Netherlands
[7] Acad Med Ctr, Dept Cardiol, Amsterdam, Netherlands
[8] Erasmus Univ, Dept Hematol, Med Ctr, Rotterdam, Netherlands
[9] Univ Utrecht, Dept Cardiol, Med Ctr, HLCU, Utrecht, Netherlands
[10] Acad Hosp Maastricht, Dept Cardiol, Maastricht, Netherlands
[11] Univ Groningen, Dept Cardiol, Med Ctr, Groningen, Netherlands
关键词
genetics; restenosis; risk factors; inflammation; angioplasty;
D O I
10.1161/CIRCULATIONAHA.105.536268
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - Restenosis is a negative effect of percutaneous coronary intervention (PCI). No clinical factors are available that allow good risk stratification. However, evidence exists that genetic factors are important in the restenotic process as well as in the process of inflammation, a pivotal factor in restenosis. Association studies have identified genes that may predispose to restenosis, but confirmation by large prospective studies is lacking. Our aim was to identify polymorphisms and haplotypes in genes involved in inflammatory pathways that predispose to restenosis. Methods and Results - The GENetic DEterminants of Restenosis ( GENDER) project is a multicenter prospective study, including 3104 consecutive patients after successful PCI. Forty-eight polymorphisms in 34 genes in pathways possibly involved in the inflammatory process were analyzed. The 16Gly variant of the beta(2)-adrenergic receptor gave an increased risk of target vessel revascularization (TVR). The rare alleles of the CD14 gene (- 260T/T), colony-stimulating factor 2 gene (117Thr/Thr), and eotaxin gene (- 1328A/A) were associated with decreased risk of TVR. However, through the use of multiple testing corrections with permutation analysis, the probability of finding 4 significant markers by chance was 12%. Conclusions - Polymorphisms in 4 genes considered involved in the inflammatory reaction showed an association with TVR after PCI. Our results may contribute to the unraveling of the restenotic process. Given the explorative nature of this analysis, our results need to be replicated in other studies.
引用
收藏
页码:2417 / 2425
页数:9
相关论文
共 28 条
[1]   Current PTCA practice and clinical outcomes in the Netherlands: the real world in the pre-drug-eluting stent era [J].
Agema, WRP ;
Monraats, PS ;
Zwinderman, AH ;
de Winter, RJ ;
Tio, RA ;
Doevendans, PAFM ;
Waltenberger, J ;
de Maat, MPM ;
Frants, RR ;
Atsma, DE ;
van der Laarse, A ;
van der Wall, EE ;
Jukema, JW .
EUROPEAN HEART JOURNAL, 2004, 25 (13) :1163-1170
[2]   Genetic aspects of restenosis after percutaneous coronary interventions - Towards more tailored therapy [J].
Agema, WRP ;
Jukema, JW ;
Pimstone, SN ;
Kastelein, JJP .
EUROPEAN HEART JOURNAL, 2001, 22 (22) :2058-2074
[3]   Linkage and association with the NOS2A locus on chromosome 17q11 in multiple sclerosis [J].
Barcellos, LF ;
Begovich, AB ;
Reynolds, RL ;
Caillier, SJ ;
Brassat, D ;
Schmidt, S ;
Grams, SE ;
Walker, K ;
Steiner, LL ;
Cree, BAC ;
Stillman, A ;
Lincoln, RR ;
Pericak-Vance, MA ;
Haines, JL ;
Erlich, HA ;
Hauser, SL ;
Oksenberg, JR .
ANNALS OF NEUROLOGY, 2004, 55 (06) :793-800
[4]   New approaches to preventing restenosis [J].
Bhargava, B ;
Karthikeyan, G ;
Abizaid, AS ;
Mehran, R .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7409) :274-279
[5]   Cytokine gene polymorphism in human disease: on-line databases, Supplement 1 [J].
Bidwell, J ;
Keen, L ;
Gallagher, G ;
Kimberly, R ;
Huizinga, T ;
McDermott, MF ;
Oksenberg, J ;
McNicholl, J ;
Pociot, F ;
Hardt, C ;
D'Alfonso, S .
GENES AND IMMUNITY, 2001, 2 (02) :61-70
[6]   Nitric oxide synthase gene therapy for cardiovascular disease [J].
Chen, AF ;
Ren, J ;
Miao, CY .
JAPANESE JOURNAL OF PHARMACOLOGY, 2002, 89 (04) :327-336
[7]   A multilocus genotyping assay for candidate markers of cardiovascular disease risk [J].
Cheng, S ;
Grow, MA ;
Pallaud, C ;
Klitz, W ;
Erlich, HA ;
Visvikis, S ;
Chen, JJ ;
Pullinger, CR ;
Malloy, MJ ;
Siest, G ;
Kane, JP .
GENOME RESEARCH, 1999, 9 (10) :936-949
[8]   Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis [J].
de Maat, MPM ;
Jukema, JW ;
Ye, S ;
Zwinderman, AH ;
Moghaddam, PH ;
Beekman, M ;
Kastelein, JJP ;
van Boven, AJ ;
Bruschke, AVG ;
Humphries, SE ;
Kluft, C ;
Henney, AM .
AMERICAN JOURNAL OF CARDIOLOGY, 1999, 83 (06) :852-856
[9]   Chemokines in patients with ischaemic heart disease and the effect of coronary angioplasty [J].
Economou, E ;
Tousoulis, D ;
Katinioti, A ;
Stefanadis, C ;
Trikas, A ;
Pitsavos, C ;
Tentolouris, C ;
Toutouza, MG ;
Toutouzas, P .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2001, 80 (01) :55-60
[10]   Drug-eluting stents in vascular intervention [J].
Fattori, R ;
Piva, T .
LANCET, 2003, 361 (9353) :247-249